Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Sponsor
China Medical University Hospital
Study ID
NCT06354387
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death and the second most deadly malignancy in Taiwan. Despite decades' intensive studies, surgery and local-regional chemo-embolization, radio-frequency ablation or radiation therapy remain the mainstay of HCC treatments.

Key Dates

Start date
Feb 16, 2022
Status verified
Mar 2026
Primary completion
Feb 28, 2026
Completion
Feb 28, 2026

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: single arm
    open label

Primary Outcome Measure

Objective response rate(ORR) [ Time Frame: Baseline to EOT (up to 52 weeks) ]

Related Studies